Volume 21 Number 6
30 June 2019

Home > Publications > Current Neuro-Oncology > Volume 21, Year 2019 > Number 6, 30 June

Marafi F, Sasikumar A, Fathallah W, Esmail A.
18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence.
Clin Nucl Med. 2019 Jun 1, 202045(1):e61-e62. doi: 10.1097/RLU.0000000000002668. PMID: 31162269. Case report. ˍ

Wang S, Yao F, Lu X, Li Q, Su Z, Lee JH, Wang C, Du L.
Temozolomide promotes immune escape of GBM cells via upregulating PD-L1.
Am J Cancer Res. 2019 Jun 1, 2019;9(6):1161-1171. PMID: 31285949. Laboratory investigation. ˍ

Du XJ, Li XM, Cai LB, Sun JC, Wang SY, Wang XC, Pang XL, Deng ML, Chen FF, Wang ZQ, Chen FR, Zhang HH, Wang HY, Piedra P, Chen ZP, Lin J, Wu SX.
Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial.
J Cancer. 2019 Jun 2, 2019;10(14):3214-3223. doi: 10.7150/jca.30123. PMID: 31289592. Interventional study. ˍ

Jiang H, Zeng W, Ren X, Cui Y, Li M, Yang K, Elbaroody M, Lin S.
Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.
J Neurooncol. 2019 Jun 7, 2019;144(1):127-135. doi: 10.1007/s11060-019-03211-1. PMID: 31175579. Observational study. ˍ

Jairam V, Kann BH, Park HS, Miccio JA, Beckta JM, Yu JB, Prabhu RS, Gao SJ, Mehta MP, Curran WJ, Bindra RS, Contessa JN, Patel KR.
Defining an Intermediate-risk Group for Low-grade Glioma: A National Cancer Database Analysis.
Anticancer Res. 2019 Jun 8, 2019;39(6):2911-2918. doi: 10.21873/anticanres.13420. PMID: 31177129. Observational study. ˍ

Smith CJ, Fairres MJ, Myers CS, Chapple KM, Klysik M, Karis JP, Youssef E, Smith KA.
Long-term outcome data from 121 patients treated with Gamma Knife stereotactic radiosurgery as salvage therapy for focally recurrent high-grade gliomas.
J Radiosurg SBRT. 2019 [Jun 9];6(3):199-207. PMID: 31998540. Observational study. ˍ

Alimohammadi E, Bagheri SR, Salehi AS, Rizevandi P, Rezaie Z, Abdi A.
Prognostic factors in patients with glioblastoma multiforme: focus on the pathologic variants.
Acta Neurol Belg. 2019 Jun 20, 2020;120(6):1341-1350. doi: 10.1007/s13760-019-01171-x. PMID: 31222512. Observational study. ˍ

Tsang DS, Oliveira C, Bouffet E, Hawkins C, Ramaswamy V, Yee R, Tabori U, Bartels U, Huang A, Millar BA, Crooks B, Bowes L, Zelcer S, Laperriere N.
Repeat irradiation for children with supratentorial high-grade glioma.
Pediatr Blood Cancer. 2019 Jun 17, 2019;66(9):e27881. doi: 10.1002/pbc.27881. PMID: 31207154. Observational study. ˍ

Xia H, Zhong D, Wu X, Li J, Yang Y, Sun X.
Medulloblastomas in cerebellopontine angle: Epidemiology, clinical manifestations, imaging features, molecular analysis and surgical outcome.
J Clin Neurosci. 2019 Jun 22, 2019;67:93-98. doi: 10.1016/j.jocn.2019.06.013. PMID: 31239198. Observational study. ˍ

Gupta T, Maitre M, Sastri GJ, Krishnatry R, Shirsat N, Epari S, Sahay A, Chinnaswamy G, Patil V, Shetty P, Moiyadi A.
Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping.
J Neurooncol. 2019 Jun 24, 2019;144(2):283-291. doi: 10.1007/s11060-019-03225-9. PMID: 31236820. Observational study. ˍ

Bleil CB, Bizzi JWJ, Bedin A, de Oliveira FH, Antunes ÁCM.
Survival and prognostic factors in childhood medulloblastoma: A Brazilian single center experience from 1995 to 2016.
Surg Neurol Int. 2019 Jun 25, 2019;10:120. doi: 10.25259/SNI-237-2019. PMID: 31528456. Observational study. ˍ

Chatzikonstantinou G, Ulrich P, Archavlis E, Zamboglou N, Strouthos I, Zoga E, Baltas D, Tselis N.
Interstitial high-dose-rate brachytherapy in the primary treatment of inoperable glioblastoma multiforme.
J Contemp Brachytherapy. 2019 Jun 28, 2019;11(3):215-220. doi: 10.5114/jcb.2019.85722. PMID: 31435428. Observational study. ˍ